3-(tetrahydro-2H-pyran-4-yloxy)propan-1-ol | 1236764-47-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 3-(tetrahydro-2H-pyran-4-yloxy)propan-1-ol
• 英文别名: 3-(Oxan-4-yloxy)propan-1-ol
• CAS: 1236764-47-8
• 化学式: C₈H₁₆O₃
• 分子量: 160.213
• InChiKey: UBSBSEDJYXNLDL-UHFFFAOYSA-N

物化性质

• 沸点：
  291.6±30.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[3-(benzyloxy)propoxy]tetrahydro-2H-pyran 在 10% palladium hydroxide on charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以100%的产率得到3-(tetrahydro-2H-pyran-4-yloxy)propan-1-ol
  参考文献：
  名称：

  CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP

  摘要：

  公开号：

  EP2418203B1

文献信息

• Fused ring compound and use thereof
  申请人：Suzuki Hideo

  公开号：US20100190747A1

  公开（公告）日：2010-07-29

  The present invention provides a compound represented by the formula: wherein the symbols are as described in the specification, or a salt thereof, which is useful for preventing/treating eicosanoid-associated diseases such as atherosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis and atopic dermatitis, and which has an excellent pharmacological action, physicochemical properties, etc.

  本发明提供一种化合物，其化学式如下： 其中符号如规范中所述，或其盐，用于预防/治疗与前列腺素相关的疾病，如动脉粥样硬化、糖尿病、肥胖、动脉血栓形成、哮喘、发热、疼痛、癌症、风湿病、骨关节炎和特应性皮炎等，并具有优异的药理作用、理化性质等。
• Cinnoline compounds
  申请人：——

  公开号：US20030212055A1

  公开（公告）日：2003-11-13

  The invention relatest to compounds of the formula (I) wherein either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—, or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, —NH—, —S—, —CH 2 — or a direct bond; Z is linked to any one of G 1 , G 2 , G 3 and G 4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R 1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; R a represents hydrogen; R b represents hydrogen or another value as defined herein; R 1 represents hydrogen, oxo, hydroxy, halogeno, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy, C 1-4 -alkyl, aminoC 1-4 alkyl, C 1-3 alkylaminoC 1-4 alkyl, di(C 1-3 alkyl)aminoC 1-4 alkyl, —C 1-5 alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R 2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 aklylsulphanyl, —NR 3 R 4 (wherein R 3 and R 4 , which may be the same or different, each represents hydrogen or C 1-3 alkyl), or R 5 X 1 — (wherein R 5 and X 1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  该发明涉及以下式(I)的化合物，其中G1、G2、G3、G4和G5中的任何一个是氮，其他四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任何一个自由碳原子相连；n是从0到5的整数；R1的任何取代基可能连接到吲哚、氮杂吲哚或吲唑基团的任何自由碳原子；m是从0到3的整数；Ra代表氢；Rb代表氢或本文中定义的另一个值；R1代表氢、氧代、羟基、卤代、C1-4烷基、C1-4烷氧基、C1-4烷氧基、C1-4烷基、氨基C1-4烷基、C1-3烷基氨基C1-4烷基、二(C1-3烷基)氨基C1-4烷基、—C1-5烷基(环B)，其中环B选自氮杂环丙烷基、吡咯烷基、哌啶基、哌嗪基、N-甲基哌嗪基、N-乙基哌嗪基、吗啉和硫代吗啉；R2代表氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、—NR3R4(其中R3和R4，可能相同也可能不同，各自代表氢或C1-3烷基)，或R5X1—(其中R5和X1如本文所定义)及其盐，制备这类化合物的方法，含有式I的化合物或其药学上可接受的盐作为活性成分的药物组合物，以及利用式I的化合物制备药物，用于在温血动物中产生抗血管生成和/或血管通透性降低作用。式I的化合物及其药学上可接受的盐抑制VEGF的作用，这是治疗多种疾病状态的有价值特性，包括癌症和类风湿性关节炎。
• Quinoline derivatives having vegf inhibiting activity
  申请人：——

  公开号：US20030199491A1

  公开（公告）日：2003-10-23

  The invention relates to compounds of formula (I) wherein: either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—, or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, —NH—, —S—, —CH 2 — or a direct bond; Z is linked to any one of G 1 , G 2 , G 3 and G 4 ; n is an integer from 0 to 5; m is an integer from 0 to 3; R a represents hydrogen or fluoro; R b , R 1 and R 2 are defined herein and salt thereof, process for the preparation so such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of a medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blodded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of diseases states including cancer and rheumatoid arthritis.

  该发明涉及以下式（I）的化合物：其中：G1、G2、G3、G4和G5中的任意一个是氮，其他四个是—CH—，或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、—NH—、—S—、—CH2—或直接键；Z与G1、G2、G3和G4中的任意一个相连；n是从0到5的整数；m是从0到3的整数；R代表氢或氟；Rb、R1和R2在此处定义，并且其盐，制备这种化合物的方法，含有式I的化合物或其药学上可接受的盐作为活性成分的药物组合物，以及利用式I的化合物制造用于在温血动物中产生抗血管生成和/或血管通透性降低作用的药物的用途。式I的化合物及其药学上可接受的盐抑制VEGF的作用，这是治疗多种疾病状态的有价值的特性，包括癌症和类风湿性关节炎。
• Chemical compounds
  申请人：——

  公开号：US20030207878A1

  公开（公告）日：2003-11-06

  The invention relates to compounds of the formula (I): wherein: ring C is 9 or 10-membered bicyclic heteroaromatic group containing at least one nitrogen atom in the ring attached to Z and optionally containing a further 1-3 heteroatoms, selected independently from O, S, and N, with the proviso that ring C is not a quinazoline, quinoline or cinnoline group; either any one of G 1 , G 2 , G 3 , G 4 and G 5 is nitrogen and the other four are —CH—; or G 1 , G 2 , G 3 , G 4 and G 5 are all —CH—; Z is —O—, NH—, —S—, CH 2 — or a direct substituents R 1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 2; R b represents hydrogen or another value as defined herein; R 1 represents hydrogen, hydroxy, halogeno, C 1-4 alkyl, or any other value as defined herein; R 2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylsulphanyl, —NR 3 R 4 (wherein R 3 and R 4 , which may be the same or different, each represents hydrogen or C 1-3 alkyl), or R 5 X 1 — (wherein R 5 and X 1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions

  本发明涉及具有以下化学式（I）的化合物：其中：环C是9或10元杂环脂环芳烃基团，至少含有一个氮原子连接到Z，并可选地含有另外1-3个杂原子，独立选择自O、S和N，条件是环C不是喹唑啉、喹啉或茴香啉基团；G1、G2、G3、G4和G5中的任何一个是氮，其他四个是—CH—；或者G1、G2、G3、G4和G5都是—CH—；Z是—O—、NH—、—S—、CH2—或直接取代基，R1可以连接到吲哚、氮杂吲哚或吲唑基团的任何自由碳原子处；m是0到2的整数；Rb代表氢或本文中定义的另一个值；R1代表氢、羟基、卤代基、C1-4烷基或本文中定义的任何其他值；R2代表氢、羟基、卤代基、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、—NR3R4（其中R3和R4，可能相同也可能不同，各自代表氢或C1-3烷基），或R5X1—（其中R5和X1如本文所定义），以及其盐，以及制备此类化合物的方法，制备药物组合物。
• [EN] QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS<br/>[FR] DERIVES DE QUINAZOLINE UTILISES COMME INHIBITEURS DE L'ANGIOGENESE
  申请人：ASTRAZENECA UK LTD

  公开号：WO2000047212A1

  公开（公告）日：2000-08-17

  The invention relates to the use of compounds of formula (I), wherein ring C is an 8, 9, 10, 12 or 13-membered bicyclic or tricyclic moiety which optionally may contain 1-3 heteroatoms selected independently from O, N and S; Z is -O-, -NH-, -S-, -CH2- or a direct bond; n is 0-5; m is 0-3; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C¿1-3?alkyl, C1-3alkoxy, C1-3alkylsulphanyl, -NR?3R4¿ (wherein R?3 and R4¿, which may be the same or different, each represents hydrogen or C¿1-3?alkyl), or R?5X1¿- (wherein X?1 and R5¿ are as defined herein; R1 represents hydrogen, oxo, halogeno, hydroxy, C¿1-4?alkoxy, C1-4alkyl, C1-4alkoxymethyl, C1-4alkanoyl, C1-4haloalkyl, cyano, amino, C2-5alkenyl, C2-5alkynyl, C1-3alkanoyloxy, nitro, C1-4alkanoylamino, C1-4alkoxycarbonyl, C1-4alkylsulphanyl, C1-4alkylsulphinyl, C1-4alkylsulphonyl, carbamoyl, N-C1-4alkylcarbamoyl, N,N-di(C1-4alkyl)carbamoyl, aminosulphonyl, N-C1-4alkylaminosulphonyl, N,N-di(C1-4alkyl)aminosulphonyl, N-(C1-4alkylsulphonyl)amino, N-(C1-4alkylsulphonyl)-N-(C1-4alkyl)amino, N,N-di(C1-4alkylsulphonyl)amino, a C3-7alkylene chain joined to two ring C carbon atoms, C1-4alkanoylaminoC1-4alkyl, carboxy or a group R?56X10¿ (wherein X?10 and R56¿ are as defined herein); and salts thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient and compounds of formula (I). The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

  本发明涉及使用式(I)的化合物，其中环C是一个含有1-3个杂原子（独立选择自O、N和S）的8、9、10、12或13元的双环或三环基团；Z是-O-、-NH-、-S-、-CH2-或直接键；n为0-5；m为0-3；R2代表氢、羟基、卤代、氰基、硝基、三氟甲基、C1-3烷基、C1-3烷氧基、C1-3烷基硫基、-NR3R4（其中R3和R4，可能相同或不同，每个代表氢或C1-3烷基），或R5X1-（其中X1和R5如上定义）；R1代表氢、氧代、卤代、羟基、C1-4烷氧基、C1-4烷基、C1-4烷氧甲基、C1-4烷酰基、C1-4卤代烷基、氰基、氨基、C2-5烯基、C2-5炔基、C1-3烷酰氧基、硝基、C1-4烷酰胺基、C1-4烷氧羰基、C1-4烷基硫基、C1-4烷基亚砜基、C1-4烷基磺酰基、氨基甲酰基、N-C1-4烷基氨基甲酰基、N,N-二(C1-4烷基)氨基甲酰基、氨基磺酰基、N-C1-4烷基氨基磺酰基、N,N-二(C1-4烷基)氨基磺酰基、N-(C1-4烷基磺酰基)氨基、N-(C1-4烷基磺酰基)-N-(C1-4烷基)氨基、N,N-二(C1-4烷基磺酰基)氨基、与两个环C碳原子连接的C3-7烷基链、C1-4烷酰胺基C1-4烷基、羧基或R56X10基团（其中X10和R56如上定义）；以及其盐，在制备用于在温血动物中产生抗血管生成和/或血管通透性降低效应的药物中使用，制备这种化合物的过程，包含式(I)的化合物或其药学上可接受的盐作为活性成分的制药组合物和式(I)的化合物。式(I)的化合物及其药学上可接受的盐抑制VEGF的效果，这是治疗包括癌症和类风湿性关节炎在内的许多疾病状态的有价值的属性。